THC Farmaceuticals Inc (CBDG) Fair Value & Analysis
Healthcare · US · Market cap $199K · ISIN US87243T1007
What is THC Farmaceuticals Inc really worth?
THC Farmaceuticals Inc
CBDG · US
A solid business, but trading 18% above our fair value of $0.0236.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 5 valuation models · updated 22 days ago
Fair value updated Aug 13, 2026, revised from $0.0076 to $0.0236 (+212.2%) since Jul 29, 2026. Share price +287.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($0.0237). The favourable scenario is already priced in.
- Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
- The models converge in a tight band ($0.0225 to $0.0237), unusually little disagreement for a valuation.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range $0.0002 – $0.3480 · fair‑value band $0.0225 – $0.0237 · the $0.0279 price screens above the $0.0236 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
THC Farmaceuticals Inc (CBDG) currently trades at $0.0279, while our model-based Fair Value estimate is $0.0236, implying the stock looks roughly 18.2% overvalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bull case: the Growth DCF group reads highest at a median of $0.0406 per share, and 2 of the 5 models we run sit above the $0.0279 price. Bear case: the Asset-Based group reads lowest at $0.0079, and 3 of the 5 models stay below the price. Evidence for this calculation is low.
Trailing-twelve-month revenue stands at $18.5K. Revenue grew 3.0% year over year. It earns a return on equity of −14.9%. Fundamentals as of Aug 13, 2026
Our scenario range runs from $0.0225 (bear case) to $0.0237 (bull case); at $0.0279, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 70% below its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −59% fair-value upside, at −15%, CBDG screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 5 models by family
Widest divergence: Growth DCF ($0.0406) versus Asset-Based ($0.0079). Highest evidence: FCF DCF (75).
Notify me when CBDG reaches fair value
Put CBDG on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 64 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company's machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses.
Full company description
THC Farmaceuticals, Inc. owns and operates non-financial institution cash-dispensing automated teller machines at third-party owned retail and commercial locations. The company's machines are placed in hotels, stores, bowling alleys, and other high customer traffic areas for small and medium sized businesses. As of June 30, 2015, it had a total of eight machines for public use along the Wasatch Front in the State of Utah. The company was formerly known as City Media, Inc. and changed its name to THC Farmaceuticals, Inc. in February 2015. THC Farmaceuticals, Inc. was founded in 2008 and is based in Scottsdale, Arizona. THC Farmaceuticals, Inc. operates as a subsidiary of Weed Growth Fund, Inc.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2018 – FY2025 · reported fiscal years
THC Farmaceuticals Inc reported revenue of $10.0K in FY2022 versus $12.2K in FY2018, a compound −4.9%/yr. Reported net income was −$10.4K in FY2025.
CBDG screens 18% overvalued. Compare with Vertex Pharmaceuticals Incorporated →
Peer Group
Biotechnology · 622 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $547.55 | $278.78 | −49% |
| Regeneron Pharmaceuticals, Inc REGN | $807.71 | $594.40 | −26% |
| argenx SE ARGX | €877.60 | €292.84 | −67% |
| Samsung Biologics Co 207940 | 1,518,000 KRW | 1,055,793 KRW | −30% |
| CSL Limited CSL | A$174.50 | A$141.68 | −19% |
| Alnylam Pharmaceuticals, Inc ALNY | $228.61 | $51.70 | −77% |
| Royalty Pharma plc RPRX | $60.58 | $24.22 | −60% |
| Celltrion, Inc 068270 | 190,700 KRW | 74,519 KRW | −61% |
| BeOne Medicines AG ONC | $362.51 | $111.35 | −69% |
| BioNTech SE BNTX | $111.40 | $45.66 | −59% |
Compare THC Farmaceuticals Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is THC Farmaceuticals Inc (CBDG) overvalued or undervalued?
What is the fair value of CBDG?
What is the quality score of CBDG?
What is the revenue of THC Farmaceuticals Inc (CBDG)?
What is the net profit margin of CBDG?
Watch THC Farmaceuticals Inc in the live analysis
One click puts THC Farmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.